K L Blackwell

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study
    Kimberly L Blackwell
    Department of Medicine Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 30:2585-92. 2012
  2. pmc Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells
    Xiu Rong Ren
    Department of Medicine, Duke University Medical Center, 595 LaSalle Street, Durham, NC 27710, USA
    Breast Cancer Res 14:R89. 2012
  3. pmc Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]
    Erika Hamilton
    Department of Surgery, Division of General Surgery, Duke University Medical Center, Durham, NC, USA
    J Transl Med 10:28. 2012
  4. pmc Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
    Barbara Adamo
    Department of Medicine, Division of Hematology Oncology, CB 7305, University of North Carolina, Chapel Hill, NC 27599, USA
    Breast Cancer Res 13:R125. 2011
  5. pmc Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
    Michael A Morse
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    J Transl Med 5:42. 2007
  6. pmc Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
    Brian M Nolen
    University of Pittsburgh Cancer Institute, Hillman Cancer Center, Suite 1, 19d, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
    Breast Cancer Res 10:R45. 2008
  7. doi request reprint Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
    K L Blackwell
    Department of Medicine Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Ann Oncol 20:1026-31. 2009
  8. doi request reprint Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
    Kimberly L Blackwell
    Duke University Medical Center, Durham, NC 27701, USA
    J Clin Oncol 28:1124-30. 2010
  9. ncbi request reprint HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors
    Kimberly L Blackwell
    Duke University Comprehensive Cancer Center, Durham, North Carolina, USA
    Clin Cancer Res 10:4083-8. 2004
  10. ncbi request reprint Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin
    Kimberly L Blackwell
    Division of Medical Oncology, Department of Medicine, Duke University Comprehensive Cancer Center, Erwin Road, Durham, NC 27710, USA
    Cancer Res 63:6162-5. 2003

Research Grants

  1. Antiestrogenic Effects on Tumor Angiogenesis
    Kimberly Blackwell; Fiscal Year: 2006

Collaborators

Detail Information

Publications33

  1. doi request reprint Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study
    Kimberly L Blackwell
    Department of Medicine Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 30:2585-92. 2012
    ..Final planned overall survival (OS) analysis from EGF104900 is reported here...
  2. pmc Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells
    Xiu Rong Ren
    Department of Medicine, Duke University Medical Center, 595 LaSalle Street, Durham, NC 27710, USA
    Breast Cancer Res 14:R89. 2012
    ..Thus, abrogation of persistent HER2 expression at the plasma membrane to synergize with current approaches may represent a novel therapeutic strategy...
  3. pmc Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]
    Erika Hamilton
    Department of Surgery, Division of General Surgery, Duke University Medical Center, Durham, NC, USA
    J Transl Med 10:28. 2012
    ..We wished to test the clinical safety, immunogenicity, and activity of a HER2-based cancer vaccine, when combined with lapatinib...
  4. pmc Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
    Barbara Adamo
    Department of Medicine, Division of Hematology Oncology, CB 7305, University of North Carolina, Chapel Hill, NC 27599, USA
    Breast Cancer Res 13:R125. 2011
    ..Secondary analyses included PI3K pathway activation status and associations with time to distant recurrence (TTDR) and time to BCBMs. Similar analyses were also conducted among the subset of patients with triple-negative BCBMs...
  5. pmc Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
    Michael A Morse
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    J Transl Med 5:42. 2007
    ..We proposed to address these concerns by using cancer vaccines to stimulate HER2 intracellular domain (ICD)-specific T cell and antibody responses...
  6. pmc Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
    Brian M Nolen
    University of Pittsburgh Cancer Institute, Hillman Cancer Center, Suite 1, 19d, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
    Breast Cancer Res 10:R45. 2008
    ..Multianalyte profiles may offer greater predictive power for neoadjuvant treatment response than the individual biomarkers currently in use...
  7. doi request reprint Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
    K L Blackwell
    Department of Medicine Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Ann Oncol 20:1026-31. 2009
    ..This phase II study evaluated the efficacy and safety of lapatinib in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer that progressed during prior trastuzumab therapy...
  8. doi request reprint Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
    Kimberly L Blackwell
    Duke University Medical Center, Durham, NC 27701, USA
    J Clin Oncol 28:1124-30. 2010
    ..EGF104900 compared the activity of lapatinib alone or in combination with trastuzumab in patients with ErbB2-positive, trastuzumab-refractory metastatic breast cancer (MBC)...
  9. ncbi request reprint HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors
    Kimberly L Blackwell
    Duke University Comprehensive Cancer Center, Durham, North Carolina, USA
    Clin Cancer Res 10:4083-8. 2004
    ..Plasma from 36 patients with primary tumor samples had VEGF (R&D Systems, MN) and d-dimer (American Diagnostica, Greenwich, CT) levels determined...
  10. ncbi request reprint Human recombinant erythropoietin significantly improves tumor oxygenation independent of its effects on hemoglobin
    Kimberly L Blackwell
    Division of Medical Oncology, Department of Medicine, Duke University Comprehensive Cancer Center, Erwin Road, Durham, NC 27710, USA
    Cancer Res 63:6162-5. 2003
    ..These data confirm that tumor oxygenation in nonanemic individuals may be improved through the administration of EPO, and this improvement appears to be independent of HgB effects...
  11. ncbi request reprint rHuEPO and improved treatment outcomes: potential modes of action
    Kimberly Blackwell
    Division of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Oncologist 9:41-7. 2004
    ..Therefore, additional research is warranted to further explore the biologic actions of rHuEPO and to determine their relevance to therapeutic outcome...
  12. ncbi request reprint Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma
    Kimberly Blackwell
    Division of Medical Oncology, Duke University Comprehensive Cancer Center, Durham, NC 27710, USA
    Cancer 101:77-82. 2004
    ....
  13. pmc Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification
    A S Betof
    Department of Pathology, Duke University Medical Center, Research Drive, Box 3455 DUMC, Durham, NC, USA
    Br J Cancer 106:916-22. 2012
    ..Accordingly, we examined whether expression of the endogenous hypoxia marker carbonic anhydrase IX (CA IX) is predictive of outcome in early-stage breast cancer patients treated with doxorubicin...
  14. pmc Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors
    Matthew E Hardee
    Department of Pathology, Duke University Medical Center, Durham, NC 22710, USA
    Cancer Chemother Pharmacol 63:219-28. 2009
    ..The growth factor receptor, Her2/neu, is overexpressed in 25-30% of breast tumors. Tumors that are Her2(+) may have an altered state of oxygenation, relative to Her2(-) tumors, due to differences in tumor growth rate and angiogenesis...
  15. pmc Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis
    M E Hardee
    Department of Pathology, Duke University Medical Center, Box 3893, Durham, NC 27710, USA
    Br J Cancer 93:1350-5. 2005
    ..These studies also suggest that further preclinical studies need to examine rEpo's direct tumour effects in efforts to improve the therapeutic benefits of Epo in solid tumour patients...
  16. doi request reprint The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer
    Christina I Herold
    Duke Comprehensive Cancer Center, Durham, North Carolina 27710, USA
    Breast 17:S15-24. 2008
    ..Possible differences in efficacy may be related to differences in potency. Two ongoing trials directly comparing two AIs - the Femara versus Anastrozole Clinical Evaluation and MA.27 - may provide further information...
  17. ncbi request reprint Ultrasound guided pO2 measurement of breast cancer reoxygenation after neoadjuvant chemotherapy and hyperthermia treatment
    Z Vujaskovic
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Hyperthermia 19:498-506. 2003
    ..The results of this preliminary study suggest that the combination of neoadjuvant chemotherapy and hyperthermia improves oxygenation in locally advanced breast tumours that are initially hypoxic...
  18. doi request reprint Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer
    Neil L Spector
    Duke Translational Research Oncology Program, Duke University Hospital, Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 27:5838-47. 2009
    ..The mechanisms of action of trastuzumab have not been fully elucidated, and data available to date are reviewed here. The impact of the mechanisms of action on clinical benefit also is discussed...
  19. pmc DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study
    Oana I Craciunescu
    Duke University Medical Center, Durham, NC 27710, USA
    Int J Hyperthermia 25:405-15. 2009
    ..The MPTS was extracted from pre-treatment MRI parameters, so independent of the combined therapy used...
  20. ncbi request reprint Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity
    Matthew E Hardee
    Department of Pathology, Duke University Medical Center, Box 3893, Durham, NC 27710, USA
    Mol Cancer Ther 5:356-61. 2006
    ....
  21. doi request reprint Are all aromatase inhibitors alike?
    Kimberly L Blackwell
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, P O Box 3893, Durham, NC 27710, USA
    Breast Cancer Res Treat 112:35-43. 2008
    ..No safety differences between the AIs have yet been identified. This article explores the pharmacologic and clinical differences between the AIs, based on data from clinical and preclinical studies...
  22. doi request reprint Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
    Carey K Anders
    Duke University Medical Center, Box 3841, 3829 Duke South, Red Zone, Durham, NC 27710, USA
    J Clin Oncol 26:3324-30. 2008
    ..Breast cancer arising in young women is correlated with inferior survival and higher incidence of negative clinicopathologic features. The biology driving this aggressive disease has yet to be defined...
  23. ncbi request reprint The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma
    John P Kirkpatrick
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Radiat Res 165:192-201. 2006
    ..In this nonanemic animal model of mammary adenocarcinoma, darbepoetin alfa does not significantly alter tumor growth or radioresponsiveness, even though it improves oxygenation when administered at high doses...
  24. doi request reprint Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease
    Christina I Herold
    Duke Comprehensive Cancer Center, Durham, NC 27710, USA
    Clin Breast Cancer 8:50-64. 2008
    ..Ongoing trials include head-to-head comparisons between the AIs in early-stage breast cancer; the results of these trials are eagerly anticipated and should further optimize the use of AIs...
  25. ncbi request reprint Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy
    Eric L Rosen
    Department of Radiology, Breast Imaging Division, Box 3808, Duke University Medical Center, Durham, NC 27710, USA
    AJR Am J Roentgenol 181:1275-82. 2003
    ..This study was undertaken to evaluate the ability of MRI to accurately show residual primary breast malignancy in women treated with neoadjuvant chemotherapy...
  26. pmc Age-specific differences in oncogenic pathway deregulation seen in human breast tumors
    Carey K Anders
    Division of Medical Oncology, Department of Medicine, Duke University, Durham, North Carolina, USA
    PLoS ONE 3:e1373. 2008
    ..To define the biology driving the aggressive nature of breast cancer arising in young women...
  27. pmc Hyperthermia for locally advanced breast cancer
    Timothy M Zagar
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Int J Hyperthermia 26:618-24. 2010
    ..The goal of this review is to highlight important research utilising HT in patients with LABC as well as to suggest future directions for its use...
  28. pmc Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data
    Timothy M Zagar
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Int J Hyperthermia 26:612-7. 2010
    ..In this review article, we will highlight the important prospective data that has been published regarding the combined use of hyperthermia and radiation...
  29. ncbi request reprint Erythropoietin biology in cancer
    Matthew E Hardee
    Department of Pathology, Duke University Medical Center, Durham, NC 22710, USA
    Clin Cancer Res 12:332-9. 2006
    ..This review describes Epo and EpoR biology, focusing on the pleiotropic effects of Epo on nonhematopoietic tissues as well as the expression and function of EpoR in cancer cells...
  30. pmc Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae
    Tammy J Westmoreland
    Department of Surgical Sciences, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 4:e5830. 2009
    ....
  31. ncbi request reprint Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    Howard A Burris
    The Sarah Cannon Research Institute, 250 25th Avenue N, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 23:5305-13. 2005
    ....
  32. ncbi request reprint Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
    Neil L Spector
    Department of Discovery Medicine and Clinical Pharmacology, GlaxoSmithKline, Five Moore Dr, Research Triangle Park, NC 27709 3398, USA
    J Clin Oncol 23:2502-12. 2005
    ..This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients with advanced ErbB1 and/or ErbB2-overexpressing solid malignancies...
  33. doi request reprint The significance of distant metastases in breast cancer
    Kimberly L Blackwell
    Breast 17:S1-2. 2008

Research Grants1

  1. Antiestrogenic Effects on Tumor Angiogenesis
    Kimberly Blackwell; Fiscal Year: 2006
    ..The results of this project will have profound implications, especially as clinicians begin to use the newer estrogen receptor modulating drugs for the prevention and treatment of breast cancer. ..